10:34 AM EDT, 09/27/2024 (MT Newswires) -- Alumis ( ALMS ) said Friday it yielded positive phase 2 data from the open-label extension period for its ESK-001 drug candidate at the 2024 European Academy of Dermatology and Venereology Congress being held this week in Amsterdam, Netherlands.

The 28-week data for ESK-001, a highly selective allosteric oral tyrosine kinase inhibitor now being evaluated in a phase 3 trial for the treatment of moderate-to-severe plaque psoriasis, was presented during a late-breaking oral session at the EADV congress, according to the company.

ESK-001 continued to show a favorable safety profile during the open-label extension period, with the frequency and severity of negative events remaining similar across all study arms, the company said.

Shares of Alumis ( ALMS ) were down nearly 2% in recent trading.

Price: 11.75, Change: -0.22, Percent Change: -1.84